New Treatments Extend Survival for Patients with Duchenne Muscular Dystrophy
New treatments extend survival for patients with Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare and fatal neuromuscular disease that primarily affects boys. It is characterized by the progressive degeneration of muscle fibers due to a defect in the production of dystrophin, an essential protein for muscle health. The first signs often appear in childhood, with loss of walking ability in early adolescence, followed by a decline in respiratory and cardiac functions. Without treatment, the life expectancy of patients remains limited, often into their late twenties.
Glucocorticoids, used for decades, have improved survival by slowing the progression of the disease. However, their long-term use can lead to serious side effects such as weight gain, reduced height, or bone fractures. Recently, new therapies called phosphorodiamidate morpholino oligomers have been developed. These treatments act directly on the underlying cause of the disease by allowing certain exons of the defective gene to be skipped. This partially restores the production of dystrophin, a key protein for proper muscle function.
Three of these treatments—eteplirsen, casimersen, and golodirsen—have been approved in the United States for patients with specific mutations. A recent study evaluated their impact on the survival of patients with Duchenne muscular dystrophy in a real-world setting, outside of clinical trials. Researchers analyzed data from more than 3,000 insured American patients, treated either with glucocorticoids alone or with a combination of glucocorticoids and one of these three new treatments.
The results show that patients receiving combination therapy had a nearly 70% reduced risk of mortality compared to those receiving only glucocorticoids. This significant reduction was confirmed by advanced statistical methods to limit biases and ensure the reliability of the conclusions. Among patients treated with the new drugs, eteplirsen was the most frequently used, followed by casimersen and golodirsen.
The study also revealed that more than 75% of deceased patients had circulatory or respiratory complications in the three months preceding their death. This confirms that the primary causes of mortality in these patients remain linked to cardiac and pulmonary failures, often observed at an early age.
These results suggest that adding these new treatments to glucocorticoids could offer a substantial survival advantage. Although further studies with longer follow-up are needed to confirm these findings, this advancement represents a major hope for patients and their families.
New treatments extend survival for patients with Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare and fatal neuromuscular disease that primarily affects boys. It is characterized by the progressive degeneration of muscle fibers due to a defect in the production of dystrophin, an essential protein for muscle health. The first signs often appear in childhood, with loss of walking ability in early adolescence, followed by a decline in respiratory and cardiac functions. Without treatment, the life expectancy of patients remains limited, often into their late twenties.
Glucocorticoids, used for decades, have improved survival by slowing the progression of the disease. However, their long-term use can lead to serious side effects such as weight gain, reduced height, or bone fractures.
Recently, new therapies have been developed to act directly on the underlying cause of the disease. They allow certain fragments of the defective gene to be skipped, thereby partially restoring dystrophin production.
Three of these treatments have been approved in the United States for patients with specific mutations. A recent study evaluated their impact on the survival of patients with Duchenne muscular dystrophy in a real-world setting, outside of clinical trials. Researchers analyzed data from more than 3,000 insured American patients, treated either with glucocorticoids alone or with a combination of glucocorticoids and one of these three new drugs.
The results show that patients receiving combination therapy had a nearly 70% reduced risk of mortality compared to those receiving only glucocorticoids. This significant reduction was confirmed by advanced statistical methods to limit biases and ensure the reliability of the conclusions. Among patients treated with the new drugs, the first was the most frequently used, followed by the other two.
The study also revealed that more than 75% of deceased patients had circulatory or respiratory complications in the three months preceding their death. This confirms that the primary causes of mortality in these patients remain linked to cardiac and pulmonary failures, often observed at an early age.
These results suggest that adding these new therapies to glucocorticoids could offer a substantial survival advantage. Although further research with longer follow-up is needed to confirm these findings, this advancement represents a major hope for patients and their families.
Site Sources
Official Study Source
DOI: https://doi.org/10.1007/s12325-026-03609-0
Title: A Real-World Target Trial Emulation of Eteplirsen, Casimersen, and Golodirsen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy
Journal: Advances in Therapy
Publisher: Springer Science and Business Media LLC
Authors: Sai Dharmarajan; Shannon Grabich; Richard Baxter; Aalok Nadkar; Carol Schermer